Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
66
Recruiting, industry sponsors, Infectious disease and vaccines, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,856
66 trials
Showing 1 to 25, recently updated first.
- A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single DosePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT06866405 · 550 participants (planned) · Start Apr 16, 2025 · Primary completion Feb 24, 2028
Drug: RSVpreF; Placebo · For: RSV Infection
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 99 sites in all
- A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised AdultsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07768345 · 440 participants (planned) · Start Aug 31, 2026 · Primary completion Feb 2, 2028
Drug: RSVpreF Vaccine · For: Respiratory Syncytial Virus (RSV)
Sites: Los Angeles, California; Aurora, Colorado; Washington D.C., District of Columbia · 21 sites in all
- Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyPivotal-lookingRecruiting
Gilead SciencesGilead Sciences (GILD)
NCT07682961 · 850 participants (planned) · Start Jul 14, 2026 · Primary completion Mar 2029
Drug: Lenacapavir; Lenacapavir Tablet and 4 more · For: HIV Infections
Sites: Bakersfield, California; Beverly Hills, California; Hidden Valley Lake, California · 61 sites in all
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.Pivotal-lookingRecruiting
Basilea PharmaceuticaIndustry
NCT05421858 · 450 participants (planned) · Start Dec 11, 2024 · Primary completion Jan 30, 2028
Drug: Fosmanogepix; Fosmanogepix and 6 more · For: Candidemia; Candidiasis, Invasive
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 146 sites in all
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.Pivotal-lookingRecruiting
Basilea PharmaceuticaIndustry
NCT06925321 · 234 participants (planned) · Start Aug 26, 2025 · Primary completion Feb 2028
Drug: Fosmanogepix IV infusion; Standard of care antifungal therapy and 1 more · For: Invasive Mold Infections
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 90 sites in all
- A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.Pivotal-lookingRecruiting
Beijing Continent Pharmaceutical Co, Ltd.Industry
NCT07412236 · 1,208 participants (planned) · Start Mar 23, 2026 · Primary completion Dec 30, 2028
Drug: Hydronidone (270mg); Hydronidone (Placebo Group) · For: Liver Fibrosis; Liver Fibrosis in Chronic Hepatitis B
Sites: Shanghai, China
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07629440 · 3,230 participants (planned) · Start May 29, 2026 · Primary completion Jun 5, 2029
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) · For: Pneumococcal Disease
Sites: Birmingham, Alabama; Fayetteville, Arkansas; Jonesboro, Arkansas · 134 sites in all
- Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or OlderPivotal-lookingRecruiting
GC Biopharma CorpIndustry
NCT07883928 · 1,806 participants (planned) · Start Oct 12, 2026 · Primary completion Mar 2028
Drug: vaccination of GC3114B; Vaccination of Efluelda · For: Influenza A, Influenza B; Influenza Vaccination
Sites: Seoul, South Korea
- A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated InfluenzaPivotal-lookingRecruiting
Boryung Biopharma Co., Ltd.Industry
NCT07943390 · 348 participants (planned) · Start Nov 2026 · Primary completion Apr 2027
Drug: BRC-201; Placebo · For: Influenza
Sites: Seoul, South Korea
- A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06667700 · 3,082 participants (planned) · Start Dec 2, 2024 · Primary completion Jan 26, 2031
Drug: Molnupiravir; Placebo · For: Coronavirus Disease (COVID-19)
Sites: Cullman, Alabama; Paradise Valley, Arizona; Phoenix, Arizona · 230 sites in all
- A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household ContactsPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06094010 · 1,100 participants (planned) · Start Nov 22, 2023 · Primary completion May 11, 2027
Drug: Baloxavir Marboxil · For: Influenza
Sites: Birmingham, Alabama; Harrisburg, Arkansas; Miami, Florida · 52 sites in all
- A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese ParticipantsPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07827599 · 325 participants (planned) · Start Oct 16, 2026 · Primary completion Apr 30, 2027
Drug: Baloxavir marboxil; Placebo · For: Influenza, Human; Respiratory Tract Infections; Post-exposure Prophylaxis
Sites: Guangzhou, China; Zunyi, China; Mianyang, China · 20 sites in all
- A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe DiseasePivotal-lookingRecruiting
ShionogiIndustry
NCT07743580 · 2,000 participants (planned) · Start Sep 14, 2026 · Primary completion Jun 30, 2028
Drug: Secutrelvir; Placebo · For: SARS-CoV-2
Sites: Coral Gables, Florida; Hialeah, Florida; Miami, Florida · 52 sites in all
- Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibPivotal-lookingRecruiting
Incyte CorporationIncyte (INCY)
NCT06855498 · 600 participants (planned) · Start Feb 28, 2025 · Primary completion Feb 28, 2028
Drug: povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Montgomery, Alabama; Phoenix, Arizona · 305 sites in all
- Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07890454 · 6,000 participants (planned) · Start Oct 28, 2026 · Primary completion Dec 28, 2027
Drug: IIV-HD (standalone); NVXC19 (EU licensed, standalone) and 2 more · For: Immunization; Healthy Volunteers; COVID-19 Immunization and 1 more
Sites: Wroclaw, Poland; Gdynia, Poland
- VE303 for Prevention of Recurrent Clostridioides Difficile InfectionPivotal-lookingRecruiting
Vedanta Biosciences, Inc.Industry
NCT06237452 · 852 participants (planned) · Start May 20, 2024 · Primary completion Jun 2027
Drug: VE303; Placebo · For: Clostridium Difficile; Clostridium Difficile Infections; Clostridium Difficile Infection Recurrence and 7 more
Sites: Huntsville, Alabama; Chandler, Arizona; Phoenix, Arizona · 215 sites in all
- A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentPivotal-lookingRecruiting
ViiV HealthcareGSK (GSK)
NCT07393659 · 197 participants (planned) · Start Jul 21, 2026 · Primary completion Sep 14, 2032
Drug: Fostemsavir; Dolutegravir (DTG)/ Lamivudine (3TC) · For: HIV Infections
Sites: Bucharest, Romania; Durban, South Africa; Jouberton, South Africa · 9 sites in all
- Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis BPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07606950 · 540 participants (planned) · Start Jul 17, 2026 · Primary completion Jun 2028
Drug: HRS-5635 Injection; Placebo · For: Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
Sites: Guangzhou, China
Grifols Therapeutics LLCIndustry
NCT05645107 · 386 participants (planned) · Start Dec 26, 2022 · Primary completion Aug 2029
Drug: Xembify; Placebo · For: Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia and 2 more
Sites: Bullhead City, Arizona; Huntington Park, California; St. Petersburg, Florida · 62 sites in all
- Study of BK1803 in Healthy InfantsPivotal-lookingRecruiting
Tanabe Pharma CorporationIndustry
NCT07793513 · 344 participants (planned) · Start Oct 21, 2026 · Primary completion Apr 2029
Drug: BK1803; GOBIK Aqueous Suspension Syringes and 1 more · For: Pertussis; Diphtheria; Tetanus and 3 more
Sites: Fukui-shi, Japan; Fukuoka, Japan; Isesaki, Japan · 33 sites in all
- A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedPivotal-lookingRecruiting
ViiV HealthcareGSK (GSK)
NCT07650916 · 564 participants (planned) · Start Jun 25, 2026 · Primary completion Aug 13, 2029
Drug: CAB ULA; RPV ULA and 2 more · For: HIV
Sites: Phoenix, Arizona; Bakersfield, California; Los Angeles, California · 111 sites in all
- An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07665437 · 710 participants (planned) · Start Jul 10, 2026 · Primary completion Oct 15, 2031
Drug: Remibrutinib · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Fort Smith, Arkansas; North Little Rock, Arkansas · 61 sites in all
- A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy InfantsPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07573462 · 2,400 participants (planned) · Start May 4, 2026 · Primary completion Dec 30, 2028
Drug: PG4; 20-valent pneumococcal conjugate vaccine (20vPnC) · For: Pneumococcal Disease
Sites: Estero, Florida; Fort Lauderdale, Florida; Fort Myers, Florida · 91 sites in all
- Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV DiseasePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07839871 · 920 participants (planned) · Start Sep 22, 2026 · Primary completion Mar 30, 2031
Drug: RSVpreF; Placebo · For: Respiratory Syncytial Virus (RSV)
Sites: Durham, North Carolina; Cincinnati, Ohio; South Euclid, Ohio · 20 sites in all
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07266831 · 570 participants (planned) · Start Dec 18, 2025 · Primary completion Feb 1, 2029
Drug: ISL; ULO and 4 more · For: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Sites: Los Angeles, California; Denver, Colorado; Washington D.C., District of Columbia · 56 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.